Literature DB >> 17004096

Cerebral malaria in spite of peripheral parasite clearance in a patient treated with atovaquone/proguanil.

Stefanie Koch1, Klaus Göbels, Joachim Richter, Mark Oette, Dieter Häussinger.   

Abstract

Cerebral malaria, the most frequent complication of falciparum malaria, is usually predicted by an increased count of asexual parasites in peripheral blood. We report a case of a female returnee from Ghana who developed cerebral malaria in spite of parasite clearance in peripheral blood after therapy with atovaquone/proguanil.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 17004096     DOI： 10.1007/s00436-006-0317-6

Source DB:  PubMed          Journal:  Parasitol Res        ISSN： 0932-0113            Impact factor:   2.289


  8 in total

1.  Multiresistant falciparum malaria cured using atovaquone and proguanil.

Authors:  T J Blanchard; D C Mabey; A Hunt-Cooke; G Edwards; D B Hutchinson; S Benjamin; P L Chiodini
Journal:  Trans R Soc Trop Med Hyg       Date:  1994 Nov-Dec       Impact factor: 2.184

2.  Atovaquone-proguanil versus chloroquine-proguanil for malaria prophylaxis in non-immune travellers: a randomised, double-blind study. Malarone International Study Team.

Authors:  B Høgh; P D Clarke; D Camus; H D Nothdurft; D Overbosch; M Günther; I Joubert; K C Kain; D Shaw; N S Roskell; J D Chulay
Journal:  Lancet       Date:  2000-12-02       Impact factor: 79.321

3.  Atovaquone-proguanil versus mefloquine for malaria prophylaxis in nonimmune travelers: results from a randomized, double-blind study.

Authors:  D Overbosch; H Schilthuis; U Bienzle; R H Behrens; K C Kain; P D Clarke; S Toovey; J Knobloch; H D Nothdurft; D Shaw; N S Roskell; J D Chulay
Journal:  Clin Infect Dis       Date:  2001-09-05       Impact factor: 9.079

4.  Atovaquone and proguani hydrochloride compared with chloroquine or pyrimethamine/sulfodaxine for treatment of acute Plasmodium falciparum malaria in Peru.

Authors:  A Llanos-Cuentas; P Campos; M Clendenes; C J Canfield; D B Hutchinson
Journal:  Braz J Infect Dis       Date:  2001-04       Impact factor: 1.949

Review 5.  Malarone (atovaquone and proguanil hydrochloride): a review of its clinical development for treatment of malaria. Malarone Clinical Trials Study Group.

Authors:  S Looareesuwan; J D Chulay; C J Canfield; D B Hutchinson
Journal:  Am J Trop Med Hyg       Date:  1999-04       Impact factor: 2.345

6.  Screening for mutations related to atovaquone/proguanil resistance in treatment failures and other imported isolates of Plasmodium falciparum in Europe.

Authors:  Ole Wichmann; Nikolai Muehlberger; Tomas Jelinek; Michael Alifrangis; Gabriele Peyerl-Hoffmann; Marion Muhlen; Martin P Grobusch; Joaquim Gascon; Alberto Matteelli; Hermann Laferl; Zeno Bisoffi; Stephan Ehrhardt; Juan Cuadros; Christoph Hatz; Ida Gjorup; Paul McWhinney; Jiri Beran; Saraiva da Cunha; Marco Schulze; Herwig Kollaritsch; Peter Kern; Graham Fry; Joachim Richter
Journal:  J Infect Dis       Date:  2004-09-28       Impact factor: 5.226

7.  Malarone treatment failure and in vitro confirmation of resistance of Plasmodium falciparum isolate from Lagos, Nigeria.

Authors:  Quinton L Fivelman; Geoffrey A Butcher; Ipemida S Adagu; David C Warhurst; Geoffrey Pasvol
Journal:  Malar J       Date:  2002-02-08       Impact factor: 2.979

8.  Malarone treatment failure not associated with previously described mutations in the cytochrome b gene.

Authors:  Ole Wichmann; Marion Muehlen; Holger Gruss; Frank P Mockenhaupt; Norbert Suttorp; Tomas Jelinek
Journal:  Malar J       Date:  2004-06-08       Impact factor: 2.979
  8 in total
  1 in total

1.  Clinical implications of Plasmodium resistance to atovaquone/proguanil: a systematic review and meta-analysis.

Authors:  Henry M Staines; Rebekah Burrow; Beatrix Huei-Yi Teo; Irina Chis Ster; Peter G Kremsner; Sanjeev Krishna
Journal:  J Antimicrob Chemother       Date:  2018-03-01       Impact factor: 5.790
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.